Outlook Therapeutics Inc (OTLK)

Feb 28, 2025, 8:05 AM EST - 5 weeks ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 19, 2025, 9:00 AM EST - 6 weeks ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 7 weeks ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 4, 2025, 9:05 AM EST - 2 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jan 31, 2025, 8:05 AM EST - 2 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 23, 2025, 9:05 AM EST - 2 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 2 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 12:09 PM EST - 2 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Jan 16, 2025, 6:00 AM EST - 2 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 6, 2025, 7:19 AM EST - 3 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Dec 27, 2024, 8:05 AM EST - 3 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 13, 2024, 4:30 PM EST - 4 months ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 4 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 4 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

Nov 27, 2024, 9:27 AM EST - 4 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 6:50 AM EST - 4 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 6, 2024, 8:05 AM EST - 5 months ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Sep 16, 2024, 8:05 AM EDT - 7 months ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 13, 2024, 9:05 AM EDT - 7 months ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 4, 2024, 8:35 AM EDT - 7 months ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 3, 2024, 8:45 AM EDT - 7 months ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:11 AM EDT - 7 months ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Aug 14, 2024, 12:02 PM EDT - 8 months ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 8 months ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 12, 2024, 9:05 AM EDT - 8 months ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 8:35 AM EDT - 8 months ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Jul 30, 2024, 9:10 AM EDT - 8 months ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Jul 8, 2024, 8:35 AM EDT - 9 months ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 13, 2024, 5:22 PM EDT - 10 months ago

Outlook Therapeutics: Worth A Good Strong Look After CRL

Jun 13, 2024, 5:50 AM EDT - 10 months ago

Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

Jun 12, 2024, 10:00 AM EDT - 10 months ago

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

Jun 11, 2024, 9:05 AM EDT - 10 months ago

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Jun 6, 2024, 10:30 AM EDT - 10 months ago

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

May 28, 2024, 8:05 AM EDT - 11 months ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

May 16, 2024, 2:35 PM EDT - 11 months ago

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

May 15, 2024, 5:00 PM EDT - 11 months ago

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

May 13, 2024, 8:50 AM EDT - 11 months ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

May 9, 2024, 8:45 AM EDT - 11 months ago

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

May 2, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Retina World Congress 2024

Apr 29, 2024, 9:00 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Apr 15, 2024, 4:15 PM EDT - 1 year ago

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Mar 31, 2024, 9:25 AM EDT - 1 year ago

Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

Mar 22, 2024, 7:35 AM EDT - 1 year ago

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Mar 18, 2024, 5:10 PM EDT - 1 year ago

Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

Mar 12, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

Feb 14, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Jan 31, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Doses First Subject in NORSE EIGHT

Jan 23, 2024, 8:00 AM EST - 1 year ago

Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010